HilleVax’s (HLVX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of HilleVax (NASDAQ:HLVXFree Report) in a research note published on Thursday morning, Benzinga reports. They currently have a $28.00 price objective on the stock.

HilleVax Trading Up 5.5 %

NASDAQ HLVX opened at $16.75 on Thursday. The firm has a market capitalization of $832.48 million, a price-to-earnings ratio of -5.51 and a beta of 0.68. The company has a debt-to-equity ratio of 0.10, a quick ratio of 17.58 and a current ratio of 10.62. HilleVax has a one year low of $9.94 and a one year high of $20.22. The company’s 50 day moving average price is $16.11 and its 200 day moving average price is $14.45.

Insider Buying and Selling at HilleVax

In other news, insider Robert Hershberg sold 11,597 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $173,143.21. Following the completion of the sale, the insider now owns 953,831 shares of the company’s stock, valued at $14,240,696.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Robert Hershberg sold 11,597 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total value of $173,143.21. Following the completion of the transaction, the insider now directly owns 953,831 shares in the company, valued at $14,240,696.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Aditya Kohli sold 6,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $14.88, for a total transaction of $89,280.00. Following the sale, the director now directly owns 855,776 shares of the company’s stock, valued at $12,733,946.88. The disclosure for this sale can be found here. Insiders have sold 66,039 shares of company stock valued at $986,288,022 over the last three months. 29.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Catalys Pacific LLC acquired a new position in shares of HilleVax in the 4th quarter valued at approximately $21,009,000. Price T Rowe Associates Inc. MD bought a new stake in shares of HilleVax in the second quarter worth $12,037,000. Deerfield Management Company L.P. Series C raised its holdings in HilleVax by 20.3% in the third quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company’s stock valued at $53,857,000 after acquiring an additional 675,000 shares in the last quarter. Morgan Stanley boosted its stake in HilleVax by 487.0% during the 4th quarter. Morgan Stanley now owns 605,313 shares of the company’s stock valued at $10,127,000 after acquiring an additional 502,197 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in HilleVax by 27.0% during the 4th quarter. Vanguard Group Inc. now owns 1,464,840 shares of the company’s stock worth $23,511,000 after acquiring an additional 310,973 shares in the last quarter. Hedge funds and other institutional investors own 89.77% of the company’s stock.

HilleVax Company Profile

(Get Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

See Also

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.